top of page

IGT Statement on Senate Introduction of the MVP Act

Today, Senators Markwayne Mullin (R-OK), Kyrsten Sinema (AZ), Tim Scott (SC), and Maggie Hassan (NH) introduced the Senate companion to the Medicaid VBPs for Patients Act, or the MVP Act. IGT Chairman Congressman Erik Paulsen issued the following statement:

 

“We are grateful for Senators Mullin, Sinema, Scott, and Hassan's leadership in introducing this critical legislation in the Senate. Modernizing our reimbursement system to help bring gene therapies to patients who need them should be a bipartisan, bicameral effort – it’s something we all can agree on.

 

“As more gene therapies advance through the development and approval pipeline, these efforts become more critical. IGT is dedicated to working with Congress to advance this legislation and help patients and families fight genetic conditions.”

 

Several patients, researchers, and other key stakeholders have expressed support for this legislation. For more information on the MVP act, click here.

high res logo.png

The Institute for Gene Therapies advocates for a modernized regulatory and reimbursement framework that encourages the development of transformative gene therapies and promotes patient access. 

X.png
Get In Touch

Thank you. Message submitted.

IGT. © 2020 All Rights Reserved

bottom of page